lifestyle.harcourthealth.com

Author: Castle Biosciences, Inc.

Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results

February 27, 2026
Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results

February 27, 2026
Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis

February 19, 2026
Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026

February 10, 2026